Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | TDO2 | P48775 | 2/20 | 0.40 |
| ▸ | FYN | P06241 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15329337 | 0.87 | ALDH1A1 (0.41) | ALDH1A1CYP1A2CYP2C19PDGFRBPDGFRA | |
| SCHEMBL15329423 | 0.86 | TLR8 (0.49) | ALDH1A1CYP1A2CYP2C19PDGFRBPDGFRA | |
| SCHEMBL348350 | 0.86 | CYP1A2 (0.47) | ALDH1A1CYP1A2CYP2C19PDGFRBPDGFRA | |
| SCHEMBL347611 | 0.85 | ALDH1A1 (0.44) | ALDH1A1CYP1A2CYP2C19PDGFRBPDGFRA | |
| SCHEMBL15327931 | 0.85 | ALDH1A1 (0.44) | ALDH1A1CYP1A2CYP2C19PDGFRBPDGFRA | |
| SCHEMBL29430467 | 0.84 | BRD4 (0.47) | HDAC6 | |
| SCHEMBL347520 | 0.84 | BRD4 (0.47) | HDAC6 | |
| SCHEMBL28158848 | 0.84 | CA1 (0.48) | ALDH1A1CYP1A2CYP2C19PDGFRBPDGFRA | |
| SCHEMBL346309 | 0.83 | PDGFRB (0.50) | ALDH1A1CYP1A2CYP2C19PDGFRBPDGFRA | |
| SCHEMBL16516706 | 0.81 | LMNA (0.37) | ALDH1A1CYP1A2CYP2C19KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102458405-B | Novel anti-inflammatory agents | 雷斯韦洛吉克斯公司 | 2017-06-23 | — | — | CN | disclosed |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | BRD4, BMI1, BRPF3 | ALDH1A1 4671/4885CYP1A2 4781/4885CYP2C19 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.